Nature's Sunshine Products (NATR) Stock Price, News & Analysis

Company Overview

Nature’s Sunshine Products, Inc. (NASDAQ: NATR) is a global natural products company specializing in the development, manufacturing and distribution of nutritional supplements and personal care items. Founded in 1972 by Rob and Eileen Olson in Spanish Fork, Utah, the company has evolved from a small herbal shop into an international leader in botanical wellness, with its corporate headquarters now located in Lehi, Utah, and manufacturing facilities in North America and Europe.

The company’s diverse product portfolio includes herbal concentrates, vitamins, minerals, essential oils and personal care formulations under brands such as Nature’s Sunshine and Flora. Utilizing proprietary extraction techniques, stringent quality control protocols and scientific research, Nature’s Sunshine creates blends designed to support immune health, digestion, stress management, beauty and overall wellbeing. Its manufacturing processes are certified to meet international quality standards including GMP (Good Manufacturing Practices).

Nature’s Sunshine serves customers in more than 50 countries across North America, Latin America, Europe and the Asia-Pacific region. Its distribution model is built on a network of independent wellness consultants who market products through face-to-face sales, online platforms and community events. This direct-selling approach is complemented by training programs, educational resources and digital tools that help consultants deliver personalized guidance and build customer relationships.

Throughout its history, Nature’s Sunshine has placed strong emphasis on sustainability, responsible sourcing and education. The company collaborates with herbalists, nutrition scientists and academic institutions to advance botanical research and develop new product innovations. Governed by a board of directors and led by an experienced executive leadership team, Nature’s Sunshine continues to expand its global reach while fostering a culture of health, transparency and social responsibility.

Key Stats

• Today's Range: $15.39 to $15.80
• 50-Day Range: $12.41 to $16.02
• 52-Week Range: $10.81 to $18.06
• Volume: 35,062 shs
• Average Volume: 51,177 shs
• Market Capitalization: $290.65 million
• P/E Ratio: 29.71
• Dividend Yield: N/A
• Price Target: $18.33
• Consensus Rating: Buy

Nature's Sunshine Products Stock Analysis - MarketRank™

Nature's Sunshine Products scored higher than 34% of companies evaluated by MarketBeat, and ranked 761st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Nature's Sunshine Products has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nature's Sunshine Products has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nature's Sunshine Products is 29.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.29.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nature's Sunshine Products is 29.62, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.58.

Price to Book Value per Share Ratio

Nature's Sunshine Products has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.98% of the float of Nature's Sunshine Products has been sold short.

Short Interest Ratio / Days to Cover

Nature's Sunshine Products has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nature's Sunshine Products has recently increased by 37.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nature's Sunshine Products does not currently pay a dividend.

Dividend Growth

Nature's Sunshine Products does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.98% of the float of Nature's Sunshine Products has been sold short.

Short Interest Ratio / Days to Cover

Nature's Sunshine Products has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nature's Sunshine Products has recently increased by 37.79%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 1.45

News Sentiment

Nature's Sunshine Products has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Nature's Sunshine Products this week, compared to 2 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nature's Sunshine Products insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,713,796.00 in company stock.

Percentage Held by Insiders

Only 5.60% of the stock of Nature's Sunshine Products is held by insiders.

Percentage Held by Institutions

79.40% of the stock of Nature's Sunshine Products is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NATR Stock Analysis - Frequently Asked Questions

How have NATR shares performed this year?

Nature's Sunshine Products' stock was trading at $14.66 at the beginning of the year. Since then, NATR stock has increased by 7.1% and is now trading at $15.70.

How were Nature's Sunshine Products' earnings last quarter?

Nature's Sunshine Products, Inc. (NASDAQ:NATR) announced its earnings results on Tuesday, May, 6th. The company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.09. The business earned $113.25 million during the quarter, compared to analyst estimates of $109.39 million. Nature's Sunshine Products had a trailing twelve-month return on equity of 6.98% and a net margin of 2.22%.
Read the conference call transcript.

How do I buy shares of Nature's Sunshine Products?

Shares of NATR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nature's Sunshine Products own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nature's Sunshine Products investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Jabil (JBL), Meta Platforms (META) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Personal Products
• Current Symbol: NASDAQ:NATR
• CIK: 275053
• Web: www.naturessunshine.com
• Phone: (801) 341-7900
• Fax: 801-342-4305
• Employees: 850
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nature's Sunshine Products: $18.33
• High Price Target: $19.00
• Low Price Target: $18.00
• Potential Upside/Downside: +18.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.53
• Trailing P/E Ratio: 29.34
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $7.70 million
• Net Margins: 2.22%
• Pretax Margin: 4.57%
• Return on Equity: 6.98%
• Return on Assets: 4.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.41
• Quick Ratio: 1.50

Sales & Book Value

• Annual Sales: $454.36 million
• Price / Sales: 0.63
• Cash Flow: $1.24 per share
• Price / Cash Flow: 12.50
• Book Value: $8.71 per share
• Price / Book: 1.78

Miscellaneous

• Outstanding Shares: 18,460,000
• Free Float: 17,429,000
• Market Cap: $286.87 million
• Optionable: Optionable
• Beta: 1.14